The "Trump-era Administration Drug Development & Outsourcing Impact Report 2025" report has been added to ResearchAndMarkets.com's offering.
This research report presents insights from 200 US and EU biopharmaceutical professionals and examines the impact of Trump-era tariffs, trade relations, and RFK Jr.'s appointment as HHS Secretary on drug development strategies, including phase of development, budget considerations, and outsourcing expenditures with CROs and CDMOs.
Additionally, the report investigates preferences for domestic versus international CROs and CDMOs, as well as the types of vendors - such as small and mid-sized versus large/global - that sponsors are most likely to engage. The report also assesses which providers are best positioned to navigate Trump-era policies and appointments and details the information needs and support CROs and CDMOs can deliver.
Lastly, the report collects respondents' views on how RFK Jr.'s appointment may affect the NIH budget and public health.
Key Topics Covered:
I. Methodology
II. Detailed Findings
III. Discussion
IV. Demographics
Companies Featured
- IQVIA
- Catalent
- WuXi
- Charles River
- Fortrea
- ICON
- Lonza
- Parexel
- Syneos Health
- Thermo Fisher
For more information about this report visit https://www.researchandmarkets.com/r/4kglij
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320816737/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
